Given the prominent role of pDCs in SLE pathogenesis, particularly as the main producers of type I IFN, inhibiting pDC activation and exploring pDC depletion have been investigated as potential treatments for human SLE by targeting surface receptors (BDCA and CD123) on human pDCs (36, 37). This evidence concerns the gene PDC and systemic lupus erythematosus.